Literature DB >> 21852877

Brand spanking? The presumptive risks of generic antiepileptic drugs.

Scott Mintzer.   

Abstract

Year:  2011        PMID： 21852877      PMCID： PMC3117498          DOI： 10.5698/1535-7511-11.2.54

Source DB:  PubMed          Journal:  Epilepsy Curr        ISSN： 1535-7511            Impact factor:   7.500


× No keyword cloud information.
  5 in total

Review 1.  Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability.

Authors:  Meir Bialer; Kamal K Midha
Journal:  Epilepsia       Date:  2010-04-08       Impact factor: 5.864

2.  Effectiveness of first antiepileptic drug.

Authors:  P Kwan; M J Brodie
Journal:  Epilepsia       Date:  2001-10       Impact factor: 5.864

3.  The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.

Authors:  Mei Sheng Duh; Frederick Andermann; Pierre Emmanuel Paradis; Jennifer Weiner; Ranjani Manjunath; Pierre-Yves Crémieux
Journal:  Dis Manag       Date:  2007-08

4.  Lamotrigine in pregnancy: clearance, therapeutic drug monitoring, and seizure frequency.

Authors:  P B Pennell; L Peng; D J Newport; J C Ritchie; A Koganti; D K Holley; M Newman; Z N Stowe
Journal:  Neurology       Date:  2007-11-28       Impact factor: 9.910

5.  The risks and costs of multiple-generic substitution of topiramate.

Authors:  M S Duh; P E Paradis; D Latrémouille-Viau; P E Greenberg; S P Lee; M B Durkin; G J Wan; M F T Rupnow; J LeLorier
Journal:  Neurology       Date:  2009-06-16       Impact factor: 9.910
  5 in total
  3 in total

1.  Brand Spanking II: Attack of the Clones (or, The Phantom Menace).

Authors:  Scott Mintzer
Journal:  Epilepsy Curr       Date:  2016 Sep-Oct       Impact factor: 7.500

2.  Generic substitution of lamotrigine among medicaid patients with diverse indications: a cohort-crossover study.

Authors:  Daniel M Hartung; Luke Middleton; Leanne Svoboda; Jessina C McGregor
Journal:  CNS Drugs       Date:  2012-08-01       Impact factor: 5.749

3.  Bias within economic evaluations - the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug.

Authors:  Jason R Guertin; Dominic Mitchell; Farzad Ali; Jacques LeLorier
Journal:  Clinicoecon Outcomes Res       Date:  2015-10-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.